The validation of Virtual Physiological Human (VHP) simulation models and the assessment of their potential clinical and socio-economic impact on both individual stakeholders like clinicians and society was the topic of this webinar. It was organised by the Center for Physics-based Simulation of Biological Structures (SIMBIOS) at Stanford University, California, USA and empirica in the context of the NMS Physiome project, a cooperation of two of the largest global research projects focusing on predictive, personalised and integrative musculoskeletal medicine: the Osteoporotic Virtual Physiological Human (VPHOP) project supported by the European Commission and SIMBIOS, funded by the US National Institutes of Health.
The timeliness of the chosen topic, presented by empirica researchers Dr. Karl Stroetmann and Dr. Rainer Thiel was underlined by the attendance of more than 50 biocomputational modellers and researchers as well as representatives of RTD funding agencies worldwide. The interest of participants was also reflected in a vivid Q&A session as part of the webinar.
The Virtual Physiological Human (VPH) is a framework of methods and technologies that, once fully established, is expected to make possible the virtual investigation of the human body as a whole. Started in Europe in 2005, it has rapidly grown to become one of the research priorities of the Information and Communication Technologies Programme of the EU Seventh Framework Programme for Research and Technological Development, which runs from 2007 to 2013.
In the US, VPH-type research is funded by all the federal agencies that participate in the Interagency Modeling and Analysis Group (IMAG), whose grantees are coordinated in the Multi-Scale Modeling (MSM) consortium.
NMS Physiome is an international project co-funded by the European Commission Seventh Framework Programme for Research and Technological Development. empirica is a partner in this consortium, like in the projects VPHOP, VPH-Share and Discipulus.
Please follow this link to download or view the webinar: Assessing Clinical and Economic Benefits of Biocomputational Models